OR WAIT null SECS
© 2022 MJH Life Sciences and Consultant Live. All rights reserved.
November 26, 2022
The pooled proportions of virological relapse and clinical relapse after discontinuing treatment in cirrhotic patients was 55.23 and 43.56%, respectively.
November 25, 2022
Investigators aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.
Factors including trust of information, fear, and resilience were related to insomnia and suicidal thoughts in healthcare workers, general population and outpatients.
November 24, 2022
Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.
Why patience is key following the major FDA decision earlier this year.
November 23, 2022
An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.
A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.
New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.
Enhanced ellipsoid integrity, greater outer retinal thickness, and decreased GA were associated with increased BCVA gains with risuteganib.
A cohort study aimed to examine the risk of overdose when treating patients with benzodiazepines compared with alternative therapies for sleep disorders, specifically in young people.